Navigation Links
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
Date:6/28/2008

ing the receptor pharmacology data entitled "Improved Dihydroergotamine (DHE) Pharmacology Following Orally-Inhaled Delivery." In addition to this study, the Company presented five posters relating to the MAP0004 program, including:

-- Newer Acute Migraine Specific Drugs May Provide Improved Sustained Relief and Freedom Over 24 and 48 Hours Post Dosing

-- Chronic Inhalation Toxicological Assessment of Dihydroergotamine in Dogs

-- Assessment of QTc Effect of DHE When Delivered Via the Lung by the Tempo Inhaler

-- MAP0004, an Orally Inhaled Formulation of DHE, Delivers Faster and More Consistent Blood Levels of the Drug Compared to Traditional Oral, Subcutaneous, Intramuscular, and Intranasal Formulations of DHE

-- Systemic Pharmacokinetics of DHE When Delivered Via the Lung to Asthmatics by the Tempo Inhaler

About MAP0004

MAP0004 is a proprietary orally inhaled version of dihydroergotamine, or DHE, intended to treat migraine. In the Company's Phase 2 efficacy study, MAP0004 provided pain relief as early as within ten minutes of dosing, and this relief was sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia. Based on these results, as well as independent research that concludes that patients prefer migraine therapies providing fast onset, pain relief, sustained pain relief and safety, the Company believes that MAP0004 has the potential to be a first-line therapy for migraine patients. Historically, estimated onset of significant pain relief with oral triptans, the class of drugs most often prescribed for treating migraine, occurs between 45 and 90 minutes after dosing. In 2007, triptans generated sales of approximately $2.2 billion in the United States, according to data published by IMS Health.

MAP0004 is designed to be an easy to use, non-invasive, at-home therapy that patients self-administer using the Company's proprietary hand-held
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
6. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
7. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
8. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015 (Family Features) Which health ... you,re like most adults, monitoring your weight, cholesterol, and ... routine. But what about vision care? ... adults reach their 40s, they often start to notice ... daily lives and job performance. Whether having difficulty reading ...
(Date:5/5/2015)... LOUIS and NIJMEGEN, the ... EndoStim, a medical device company developing lower esophageal ... (GERD) announced long-term, 3-year, positive safety and efficacy ... reflux symptoms of both heartburn and regurgitation and ... esophageal pH test) with near-complete elimination of dependence ...
(Date:5/5/2015)... SAN FRANCISCO , May 5, 2015  IQPC,s ... is pleased to announce the chairman of the Summit Mr. ... at Wipro. He will be joined by the expert speaker ... and more this May 11 – 12, at The Hotel ... The agenda is available for download on the event ...
Breaking Medicine Technology:Eye Care as You Age 2Eye Care as You Age 3Eye Care as You Age 4Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 2Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 3Phani Bidarahalli from Wipro to chair the upcoming 19th Software Design for Medical Devices Summit in San Francisco 2
(Date:5/5/2015)... 05, 2015 Leveraging the industry-leading technology ... Greece, an experienced team of fertility specialists are committed ... patients around the globe. , “We’re honored that Maternity ... remains a global leader in reproductive medicine. The clinic ... specialists in the world who play an important role ...
(Date:5/5/2015)... PA (PRWEB) May 05, 2015 The 2015 ... raised $110,000 to benefit their global research, outreach and patient ... silent auction, and awards ceremony that attracted hundreds of supporters. ... of the discovery of the hepatitis B virus (HBV) by ... Blumberg received the Nobel Prize in Medicine for his discovery ...
(Date:5/5/2015)... 05, 2015 Viverae®, a health ... Inc., a leading multinational developer, manufacturer and marketer ... of vascular, urology, oncology and surgical specialty products, ... The Vanguard Award recognizes outstanding achievement in ... among Viverae’s significant client base. , Viverae reviewed ...
(Date:5/5/2015)... Sunny skies and cool temperatures made for great ... runners and walkers participated in Global Lyme Alliance’s (GLA) inaugural ... , The 5K and 10K runs and 1-and 3-mile walks ... raise funds for tick-borne disease research. The “Lyme Walk and ... merger of Lyme Research Alliance (LRA) and Tick-Borne Disease ...
(Date:5/5/2015)... 05, 2015 Skedans Systems ... BC announced the Skedans Sensor Collaboration Platform at ... and web app developers, provides tooling to deliver real ... sensors. , The Skedans Sensor Collaboration Platform is a ... the Internet of Things, Web Real Time Communications (WebRTC), ...
Breaking Medicine News(10 mins):Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 2Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 3Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2
... Treat Diseases (HTDS) www.htdsmedical.com is pleased to ... Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope). ... corporation; HTDS Enterprises, Inc., which is the parent company ... million USD on an all-stock basis. The company will ...
... Misonix, Inc. (Nasdaq: MSON ), a developer ... Europe is used for the ablation of tumors and ... a new, three year, exclusive distribution agreement with privately-held ... Saba, Israel, for the distribution of the SonaStar(TM) Ultrasonic ...
... Consumer Watchdog sent a letter to Senator ... expressing their profound disappointment that consumer advocates had ... the Massachusetts senator to formulate health care reform ... recent national polls showing the public overwhelming opposed ...
... Well Asthma is Controlled in New EnglandPROVIDENCE, R.I., Feb. ... (ALANE) has partnered with QualityMetric Incorporated of Lincoln, Rhode ... that will help asthma sufferers learn how well their ... the results with their physician.The Asthma Control Test(TM) (ACT(TM)) ...
... QINGDAO, China and ROCKVILLE, Md., Feb. 20 ... SYUT , "Synutra"), a leading infant formula,company ... seller of nutritional products,for infants, children and ... of certain production permit numbers in a ...
... Inc., (OTC Bulletin Board: EFSF) an emerging healthcare ... dermatology, environmental and nutraceutical products, outlined its growth ... 2010 during its regularly scheduled monthly investor call, ... intends to increase revenues by improving the visibility ...
Cached Medicine News:Health News:Hard To Treat Diseases (HTDS) Closes Acquisition of Mellow Hope, China 2Health News:Hard To Treat Diseases (HTDS) Closes Acquisition of Mellow Hope, China 3Health News:Misonix Announces New Distribution Agreement for Israel 2Health News:Misonix Announces New Distribution Agreement for Israel 3Health News:Consumer Watchdog to U.S. Senate: Don't Leave Consumers Out of Health Reform Debate, Public Opposes Mandatory Purchases of Private Insurance & Supports Opening Medicare to Everyone 2Health News:American Lung Association of New England Launches Online Asthma Control Test 2Health News:American Lung Association of New England Launches Online Asthma Control Test 3Health News:American Lung Association of New England Launches Online Asthma Control Test 4Health News:Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification 2Health News:Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification 3Health News:eFoodSafety.com Provides Revenue Guidance for FY 2010 2Health News:eFoodSafety.com Provides Revenue Guidance for FY 2010 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: